Sugi Predict

Sugi Predict / Compounds / SCHEMBL939405

SCHEMBL939405

SCHEMBL939405

N[C@@H](CN1CCNCC1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM5 P08912 1/20 0.41
▸ CHRM3 P20309 1/20 0.41
▸ DPP7 Q9UHL4 1/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ GRM5 P41594 2/20 0.39
▸ GRM1 Q13255 2/20 0.39
▸ GRM3 Q14832 2/20 0.39
▸ GSR P00390 2/20 0.39
▸ GRIA1 P42261 2/20 0.39
▸ GRIA2 P42262 2/20 0.39
▸ GRIA4 P48058 2/20 0.39
▸ GRIK5 Q16478 2/20 0.39
▸ GRM8 O00222 1/20 0.39
▸ GRM6 O15303 1/20 0.39
▸ GRIN2D O15399 1/20 0.39
▸ GRIN3B O60391 1/20 0.39
▸ GRIK1 P39086 1/20 0.39
▸ GRIA3 P42263 1/20 0.39
▸ SLC1A3 P43003 1/20 0.39
▸ SLC1A2 P43004 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1175906 1.00 CHRM5 (0.41) CHRM5CHRM3DPP7CYP1A2GRM5
SCHEMBL26912060 1.00 CHRM5 (0.41) CHRM5CHRM3DPP7CYP1A2GRM5
SCHEMBL10000693 0.90 CHRM5 (0.41) CHRM5CHRM3DPP7CYP1A2GRM5
SCHEMBL2267331 0.82 ANPEP (0.44) CHRM5CHRM3DPP7CYP1A2GRM5
SCHEMBL2267325 0.82 ANPEP (0.44) CHRM5CHRM3DPP7CYP1A2GRM5
SCHEMBL31557711 0.81 CHRM5 (0.44) CHRM5CHRM3ALDH1A1KDM4ESMN1; SMN2
SCHEMBL25661087 0.81 DPP7 (0.52) DPP7CYP1A2GRM5GRM1GRM3
SCHEMBL5322593 0.81 DPP7 (0.52) DPP7CYP1A2GRM5GRM1GRM3
SCHEMBL384886 0.79 DPP7 (0.55) DPP7CYP1A2GRM5GRM1GRM3
SCHEMBL2065181 0.79 DPP7 (0.55) DPP7CYP1A2GRM5GRM1GRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117750978-A Synthetic peptide shuttle bioconjugates for intracellular cargo delivery 费尔丹生物公司 2024-03-22 — — CN claimed
EP-4313159-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY Feldan Bio Inc. (CA) 2024-02-07 — — EP claimed
US-20230399661-A1 SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS FELDAN BIO INC. (CA) 2023-12-14 — — US claimed
US-20230383291-A1 PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION FELDAN BIO INC. (CA) 2023-11-30 — — US claimed
CN-116615227-A Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof 费尔丹生物公司 2023-08-18 — — CN claimed
CN-116615205-A Peptide-based transduction of non-anionic polynucleotide analogs for modulation of gene expression 费尔丹生物公司 2023-08-18 — — CN claimed
WO-2022204806-A1 SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY FELDAN BIO INC. (CA) 2022-10-06 — — WO claimed
US-20220204561-A1 PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY FELDAN BIO INC. (CA) 2022-06-30 — — US claimed
CN-114206902-A Method for modifying a peptide immobilized on a solid support by means of a traceless reductively cleavable linker molecule 贝兰迪克有限责任公司 2022-03-18 — — CN claimed
EP-3956348-A1 PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY Feldan Bio Inc. (CA) 2022-02-23 — — EP claimed
WO-2020210916-A1 PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY FELDAN BIO INC. (CA) 2020-10-22 — — WO claimed
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof RAYZEBIO, INC. (US) 2025-07-10 — — US disclosed
WO-2025137441-A1 RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 — — WO disclosed
WO-2025137443-A1 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF RAYZEBIO, INC. (US) 2025-06-26 — — WO disclosed
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY MERCK SHARP & DOHME LLC 2024-08-29 — — US disclosed
WO-2011095607-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY POLYPHOR AG (CH) 2011-08-11 — — WO disclosed
WO-2011060832-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY POLYPHOR AG (CH) 2011-05-26 — — WO disclosed
US-20110020343-A1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS, INC. (US) 2011-01-27 — — US disclosed
EP-2265283-A1 AURISTATIN DRUG LINKER CONJUGATES Seattle Genetics, Inc. (US) 2010-12-29 — — EP disclosed
WO-2009117531-A1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS, INC. (US) 2009-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110020343-A1 AURISTATIN DRUG LINKER CONJUGATES AURKA, AURKC, AURKB CHRM5 3031/4885CHRM3 2091/4885DPP7 1036/4885
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY TNF, TNFRSF1A, CD40 CHRM5 4339/4885CHRM3 4050/4885DPP7 1654/4885
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof SSTR2, SSTR4, SSTR5 CHRM5 2533/4885CHRM3 2079/4885DPP7 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.